For the quarter ended December 2023, Myriad Genetics (MYGN) reported revenue of $196.6 million, up 10.6% over the same period last year. EPS came in at $0.04, compared to -$0.12 in the year-ago quarter.The reported revenue represents a surprise of +1.17% over the Zacks Consensus Estimate of $194.33 million. With the consensus EPS estimate being $0.02, the EPS surprise was +100.00%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to det ...

F E B R U A R Y 2 7 , 2 0 2 4 Fourth Quarter & Full-Year 2023 Earnings ...

总收入及业务增长 - 公司在2023年实现了总收入为7.532亿美元，同比增长11%[356] - 公司在2023年的测试量同比增长35%，其中药物基因组学增长24%，遗传性癌症增长17%，产前检测增长15%[357] - 公司在2023年的季度业绩受季节性影响较小，9月30日季度的测试量仅比6月30日季度下降不到1%[362] 财务表现 - 公司在2023年完成了一次公开发行，售出744万4176股普通股，每股价格为17美元，净收益为1.176亿美元[358] - 公司在2023年的测试收入中，遗传性癌症收入增长22.3%，药物基因组学收入增长10.9%，产前检测收入增长34.9%[371] - 公司在2023年的测试成本中，测试收入成本占总收入的31.4%，较上一年有所增加[373] - 公司在2023年的研发支出占总收入的11.8%，较上一年有所增加[374] - 公司在2023年的销售、一般和管理费用占总收入的76.1%，较上一年有所增加[375] - 公司在2023年的法律和长期资产减值费用占总收入的15%，较上一年有所增加[376] - 其他收入（费用）在2023年12月31日结束的年度中减少了4.8百万美元，主要是由于本年度外币损失3.4百万美元和投资证券出售损失1.5百万美元[378] - 所得税费用（利益）在2023年12月31日结束的年度中为1.1百万美元，有效税率为0.4%[379] 资金状况及筹资活动 - 截至2023年12月31日，公司现金、现金等价物和可交易投资证券为140.9百万美元，ABL Facility下的可用性为40.7百万美元[381] - ABL Facility总最大本金承诺为115.0百万美元，截至2023年12月31日，ABL Facility下的可用性为40.7百万美元[382] - 在2023年11月，公司完成了一项公开发行普通股，募集资金117.6百万美元，用于支付尚未偿还的57.5百万美元证券集体诉讼，以及用于营运资金和一般公司用途[383] - 我们相信现有的资本资源将足以满足未来至少12个月的运营需求[384] - 截至2023年12月31日，现金、现金等价物和可交易投资证券为140.9百万美元，较2022年12月31日减少了28.8百万美元，主要是由于运营中使用了110.9百万美元的现金，以及销售可交易投资证券以资助运营[388] 现金流及投资活动 - 在2023年12月31日结束的年度中，现金流用于经营活动基本保持一致，主要是由于支付的法律和解决费用增加，但由于收入增长和费用降低，核心运营有所改善[390] - 在2023年12月31日结束的年度中，投资活动提供的现金流量增加，主要是由于来自可交易投资证券的净收益增加，以及在当前期间进行的资本支出和内部使用软件成本资本化的增加[391] - 在2023年12月31日结束的年度中，融资活动提供的现金流量增加，主要是由于公开发行普通股募集的117.6百万美元资金净额，以及ABL Facility的净款项[392] 其他信息 - 我们截至2023年12月31日在资产负债表上记录的商誉为2.874亿美元[401] - 我们的ABL融资设施的借款利率基于Prime Rate、NYFRB Rate或Secured Overnight Financing Rate（SOFR），如果借款利率增加或减少100个基点，根据2023年12月31日我们在ABL融资设施上的4,000万美元债务，我们的年度利息支出将增加或减少0.4百万美元[406] - 我们的投资组合遵循我们的书面投资政策，投资标准包括信用质量标准和对任何单一问题、发行人或投资类型的信用敞口限制。我们的投资包括各种类型和期限为一年或更短的债务证券，并被分类为可供出售[408]

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in Japan to study the prognostic and predictive value of molecular residual disease (MRD) testing. The SCRUM-MONSTAR-SCREEN-3 study will use Myriad's ultra-sensitive MRD test, Precise MRD, to monitor circulating tumor DNA (ctDNA) over time in patients diagnosed with a wide arra ...

收购交易 - Myriad Genetics, Inc.宣布完成了从Intermountain Health处收购Intermountain Precision Genomics (IPG)实验室业务的部分资产[1] 产品发展 - Myriad将继续运营TheraMap: Solid Tumor作为Precise Tumor，并计划推出Precise Liquid，提供便捷的全面基因组分析结果[2][3] 增长战略 - 收购使Myriad能够更有效地扩展和增长其肿瘤分析产品，以补充其遗传性癌症和伴随诊断测试选择[4]

Yozayo In the field of genetic testing and precision medicine, Myriad Genetics (NASDAQ: NASDAQ:MYGN) is a progressive company, which can be observed in its steady double-digit revenue growth and the upward revision of revenue guidance for the next year. The financial results of the third quarter of 2023 of the company demonstrate a strong year-over-year growth in testing volumes in various segments, such as hereditary cancer, pharmacogenomics, and prenatal testing. This upward trend is not a temporary incre ...

SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial ...

Myriad Genetics (MYGN) , a front-runner in genetic testing and precision medicine, recently announced its plans to acquire select assets from Intermountain Precision Genomics (IPG). This acquisition, including the Precise Tumor Test, the Precise Liquid Test and the Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in St. George, UT, is set to close on Feb 1, 2024.The financial terms of the deal were not disclosed.The Deal and its BenefitsBy bringing the Precise Tumor and Precise Liquid ...

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics' (IPG) laboratory business, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed. The acquisition is expected to close on February 1, 2 ...

SALT LAKE CITY, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced its support for the American Society of Clinical Oncology (ASCO)—Society of Surgical Oncology (SSO) guideline for germline testing in patients with breast cancer. The new guideline offers multi-pronged, evidence-based clinical practice recommendations. Among the guidance includes: All patients with a current or previous diagnosis of invasive breast cance ...